Case Studies in Drug Development: Statins, ACE Inhibitors & Beta-Lactams

Case Studies in Drug Development

Examining successful drug development programmes reveals how medicinal chemistry, pharmacology, and clinical science integrate. Three classes — statins, ACE inhibitors, and beta-lactams — exemplify different discovery strategies and have collectively saved millions of lives.

Statins: Enzyme Inhibitor Discovery

Cholesterol biosynthesis depends on HMG-CoA reductase (HMGCR), the rate-limiting enzyme converting HMG-CoA to mevalonate. Akira Endo at Sankyo screened fungal fermentation broths in the 1970s looking for natural HMGCR inhibitors, inspired by the evolutionary logic that fungi producing HMGCR inhibitors would compete better against cholesterol-rich organisms. He isolated compactin (mevastatin) from Penicillium citrinum.

Lovastatin (Mevacor, 1987) was the first statin approved. Its decalin ring-lactone structure closely resembles the HMG-CoA transition state, binding HMGCR with high affinity. Medicinal chemistry optimised the scaffold: simvastatin added a methyl group to lovastatin; pravastatin added a hydroxyl for improved hydrophilicity; fluvastatin introduced a fully synthetic fluorophenyl-indole core; atorvastatin (Lipitor) and rosuvastatin moved to synthetic fluorophenyl-pyrrole and pyrimidine scaffolds respectively, achieving greater potency and longer half-lives.

ACE Inhibitors: Structure-Based Design Pioneer

Bradykinin-potentiating peptides from the venom of the Brazilian lancehead pit viper Bothrops jararaca inhibited angiotensin-converting enzyme (ACE) and lowered blood pressure. Cushman and Ondetti at Squibb studied the carboxypeptidase A crystal structure as an ACE model and designed captopril (1981) — the first structure-guided drug — using a thiol zinc-binding group and a proline C-terminus mimicking the natural substrate transition state.

Captopril's thiol caused taste disturbances and rashes. Replacing thiol with carboxylate gave enalaprilat (active form) — but oral bioavailability was poor, solved by esterification to enalapril (a prodrug hydrolysed in vivo). Lisinopril added a lysine side-chain improving bioavailability without prodrug strategy. This class demonstrates how iterative SAR around a validated target transforms a venom peptide lead into daily oral medicines.

Beta-Lactams: Natural Product to Semi-Synthetic Optimisation

Penicillin G's narrow spectrum and susceptibility to β-lactamases motivated semi-synthesis from 6-aminopenicillanic acid (6-APA). Adding bulky acyl side-chains (flucloxacillin) sterically blocked β-lactamase active sites. Extended spectrum penicillins (ampicillin, amoxicillin) added an amino group to penetrate gram-negative outer membranes.

Cephalosporins, derived from Cephalosporium acremonium, offered a broader base for modification (C7 acyl and C3 substituents independently tuned). Fourth-generation cephalosporins (cefepime) achieve anti-pseudomonal activity. Carbapenems (imipenem) resist most β-lactamases. β-Lactamase inhibitors (clavulanate, tazobactam) protect co-administered penicillins. Each advance illustrates how understanding resistance mechanisms drove chemical innovation.